K
Kunpeng Liu
Researcher at Chinese Academy of Sciences
Publications - 4
Citations - 322
Kunpeng Liu is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Antibody & Coronavirus. The author has an hindex of 1, co-authored 4 publications receiving 111 citations.
Papers
More filters
Journal ArticleDOI
AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells.
Shuai Wang,Zongyang Qiu,Zongyang Qiu,Yingnan Hou,Yingnan Hou,Xiya Deng,Xiya Deng,Wei Xu,Tingting Zheng,Tingting Zheng,Peihan Wu,Peihan Wu,Shaofang Xie,Shaofang Xie,Weixiang Bian,Weixiang Bian,Chong Zhang,Zewei Sun,Kunpeng Liu,Chao Shan,Aifu Lin,Shibo Jiang,Youhua Xie,Qiang Zhou,Qiang Zhou,Lu Lu,Jing Huang,Jing Huang,Xu Li,Xu Li +29 more
TL;DR: In this paper, the tyrosine-protein kinase receptor UFO (AXL) specifically interacts with the N-terminal domain of SARS-CoV-2 S.
Journal ArticleDOI
RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates.
Xiaoyan Pan,Jian Shi,Xue Hu,Yan Wu,Zeng Liang,Yanfeng Yao,Weijuan Shang,Kunpeng Liu,Ge Gao,Weiwei Guo,Yun Peng,Shaohong Chen,Xiaoxiao Gao,Cheng Peng,Juhong Rao,Jiaxuan Zhao,Cheng Gong,Hui Zhou,Yudong Lu,Zili Wang,Xiliang Hu,WenJuan Cong,Fang Lijuan,Yongxiang Yan,Jing Zhang,Hui Xiong,Jizu Yi,Zhiming Yuan,Pengfei Zhou,Chao Shan,Gengfu Xiao +30 more
TL;DR: In this paper, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS CoV2 vaccine candidate.
Journal ArticleDOI
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.
Chunyin Gu,Xiaodan Cao,Zongda Wang,Xue Hu,Yanfeng Yao,Yiwu Zhou,Peipei Liu,Xiaowu Liu,Ge Gao,Xiao Hu,Yecheng Zhang,Zhen Chen,Li Gao,Yun Peng,Fangfang Jia,Chao Shan,Li Yu,Kunpeng Liu,Nan Li,Weiwei Guo,Guoping Jiang,Juan Min,Jianjian Zhang,Lu Yang,Meng Shi,Tianquan Hou,Yanan Li,Weichen Liang,Guoqiao Lu,Congyi Yang,Yuting Wang,Kaiwen Xia,Zheng Xiao,Jianhua Xue,Xueyi Huang,Xin Chen,Haixia Ma,Donglin Song,Zhongzong Pan,Xueping Wang,Haibing Guo,Hong Liang,Zhiming Yuan,Wuxiang Guan,Su Jun Deng +44 more
TL;DR: In this paper, the authors identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform.
Posted ContentDOI
Single-dose AAV-based vaccine induces a high level of neutralizing antibodies and provides long-term protection against SARS-CoV-2 in rhesus macaques
Dali Tong,Mei Zhang,Yunru Yang,Han Xia,Haiyang Tong,Weihong Zeng,Huan Ma,Xue Hu,Weiyong Liu,Yuan Cai,Yanfeng Yao,Yichuan Yao,Kunpeng Liu,Shifang Shan,Yajuan Li,Ge Gao,Weiwei Guo,Yun Peng,Shaohong Chen,Juhong Rao,Jiaxuan Zhao,Juan Min,Qingjun Zhu,Yanmin Zheng,Lianxin Liu,Chao Shan,Kai Zhong,Zilong Qiu,Tengchuan Jin,Zhiming Yuan,Tian Xue +30 more
TL;DR: In this paper, an adeno-associated virus (AAV)-based vaccine expressing a stable receptor-binding domain (SRBD) protein was developed to prevent the spread of SARS-CoV-2.